Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

37.48 +0.05 (+0.12%)
Streaming Delayed Price Updated: 1:22 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
The Global Pantry Reimagined: Unilever and McCormick Seal $65 Billion Merger Deal
In a move that has sent shockwaves through the global consumer staples market, Unilever (NYSE:UL) and McCormick & Company (NYSE:MKC) have officially entered into a definitive agreement to merge... 
Via MarketMinute
Topics Economy Supply Chain
News headline image
The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the... 
Via MarketMinute
News headline image
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker? ↗
One of these players is well-positioned for market leadership. 
Via The Motley Fool
News headline image
3 Absurdly Cheap Dividend Stocks to Buy in April 2026 ↗
These stocks offer high yields and trade at incredibly low earnings multiples. 
Via The Motley Fool
Topics Economy
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Goldman Sachs Forecasts 12% S&P 500 Surge in 2026: The Five Pillars of a Maturing Bull Market
As the second quarter of 2026 kicks off, the investment landscape is being defined by a renewed sense of optimism from Wall Street’s most influential voices. Goldman Sachs (NYSE: GS) has officially... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade
News headline image
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals? ↗
Via MarketBeat
News headline image
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight ↗
The U.S. Food & Drug Administration just approved Eli Lilly's GLP-1 pill orforglipron. 
Via The Motley Fool
News headline image
Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%
As of April 3, 2026, the financial landscape is witnessing a historic disconnect between gritty macroeconomic headlines and exuberant corporate fundamentals. Despite a backdrop of stubborn... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market ↗
The drugmaker hasn't said its last word yet, as the weight-loss drug battle continues to heat up. 
Via The Motley Fool
News headline image
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for... 
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require... 
Via MarketMinute
Topics Economy
News headline image
The Evolution of The Cigna Group: A Deep Dive into a Health Services Powerhouse (2026)
April 2, 2026 Introduction The Cigna Group (NYSE: CI) stands today at a pivotal crossroads, having undergone one of the most significant strategic transformations in the modern healthcare era. Long... 
Via Finterra
Topics Artificial Intelligence Economy Lawsuit
News headline image
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Eli Lilly Stock Trounced the Market Today ↗
Its first weight-loss pill was just approved by the FDA. 
Via The Motley Fool
News headline image
Eli Lilly’s $47.8 Billion Masterstroke: The Contessa Acquisition and the New Era of Pharmaceutical Dominance
INDIANAPOLIS — In a move that has sent shockwaves through the global financial markets, Eli Lilly and Company (NYSE: LLY) announced early this morning, April 1, 2026, a definitive agreement to acquire... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Could This New Approval Be a Turning Point For Novo Nordisk? ↗
The pharmaceutical giant still has plenty of work to do to recover from recent woes. 
Via The Motley Fool
News headline image
Is This Weight Loss Drug Stock a Buy After a New Approval? ↗
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful? 
Via The Motley Fool
News headline image
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY).... 
Via Finterra
Topics Economy Intellectual Property
News headline image
1 Reason This Biotech Stock Could Triple Before Year-End ↗
This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate. 
Via The Motley Fool
News headline image
1 Reason Eli Lilly Stock Is Still a Buy ↗
Eli Lilly is much more than just a weight loss stock. 
Via The Motley Fool
Topics Artificial Intelligence
Novo Nordisk: A Strong Contender in the Pharmaceutical Arena ↗
Could Novo Nordisk be the hidden gem you've been searching for? Join us as we evaluate its current market position and future prospects in this insightful episode. 
Via The Motley Fool
News headline image
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing... 
Via MarketMinute
News headline image
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy? ↗
It's not much of a contest right now. 
Via The Motley Fool
News headline image
Could Buying Eli Lilly Today Set You Up for Life? ↗
Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
What's Happening With Novo Nordisk Stock Today? ↗
Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, including the... 
Via Benzinga
News headline image
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which... 
Via MarketMinute
News headline image
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study.... 
Via MarketMinute
News headline image
Surging Oil Prices Spark Market Jitters ↗
The Motley Fool's Hidden Gems team discusses some historical disruptions in the energy market, how trends in semiconductors are reshaping the S&P 500, and why Hims & Hers stock is soaring. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.